Initial plans target European clinical trials while providing standard testing to clinicians for individual patients

NEW YORK, Jan. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Predictive Oncology just reported results for the second quarter of 2024.

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Company to Host International Roadshow the Week of January 13, 2025

BALA CYNWYD, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Predictive Oncology Inc. (NASDAQPOAI) to Renovaro Inc. is fair to Predictive shareholders.

Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data

- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications –

PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQPOAI), a leader in AI-driven drug discovery, today announced progress in its ongoing evaluation of strategic alternatives, which was announced on November 13, 2024.

Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value

Predictive Oncology (NASDAQPOAI) is announcing participation at the upcoming H.C. Wainwright 26th Annual Global Investment Conference to be held September 9-11 in New York. The company is scheduled to deliver a virtual presentation, which will be available on-demand starting Monday, September 9 at 7 a.m. ET. The Predictive Oncology management team will also host one-on-one meetings during the conference.

PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQPOAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY.

Predictive Oncology (NASDAQPOAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, is reporting on a study that demonstrates the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples available within its proprietary biobank. According to the report, the study validates highly reproducible drug response data as well as enabling and supporting the AI platform to model and predict patient outcomes on historical samples. The company has released a new white paper that discusses this study, and the importance of tumor sample viability, in greater detail.

Study further validates highly reproducible drug response data. Enables AI platform to model and predict patient outcomes on historical samples

Predictive Oncology (NASDAQPOAI) today announced its financial and operating results for the second quarter ended June 30, 2024, and provided a corporate update. The company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. In addition, it concluded Q2 2024 with $5.3 million of cash and cash equivalents, compared to $8.7 million as of December 31, 2023, and $4.1 million in stockholders’ equity as of June 30, 2024, compared to $8.3 million as of December 31, 2023.

Company to host investor call and webcast today, August 14th, at 8:30am EDT

Predictive Oncology (NASDAQPOAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, has expanded the available applications for its platform to account for patient heterogeneity, derisk drug discovery and accelerated pipeline development. The company announced that its findings demonstrate real-world applications of POI’s AI platform to support biomarker discovery, clinical trial optimization and target validation; the platform also offers a proprietary tool that accounts for patient heterogeneity and increases Probability of Technical Success. In addition, Predictive Oncology released a new white paper that discusses these capabilities in greater detail.

Findings demonstrate real-world applications of Company’s AI platform to support biomarker discovery, clinical trial optimization and target validation

Predictive Oncology (NASDAQPOAI) is a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) to accelerate oncology drug discovery and enable drug development. The company expects to report its financial results for the second quarter of fiscal 2024, ended June 30, 2024, before markets open on Wednesday, August 14, 2024. Additionally, Predictive Oncology will host a corporate update conference call and live audio webcast that same day at 8:30 a.m. ET. Interested parties can dial 877-407-3982 (toll free) or 201-493-6780 (international) and enter the conference ID 13748154.

Management to host conference call and webcast at 8:30am ET